SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Wexler who wrote (2598)8/10/2000 8:43:32 AM
From: Mike M  Read Replies (2) of 5582
 
There are some valid points here but your comparison may be a stretch.

Investors should always proceed with caution particularly when investing in small companies with few product lines and limited resources.

If your point is to avoid betting the farm on a company like GUMM then I couldn't agree with you more. Only speculative dollars should be allocated and I would caveat only if you have first hand product knowledge and truly believe in same. Until this company has published supporting data, secured adequate capital and firm marketing partnerships it is purely a speculative play and any investment should be viewed accordingly.

Any comparison of GUMM with companies that never got their product to market is shallow and misleading. The company's sales were predominantly Zicam last year. To recognize their expanded business strategy is reasonable.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News